The (apparent) sacubitril/valsartan sex interaction in heart failure with preserved ejection fraction: not the result of relaxin effects but of BNP action?!
作者信息
Dschietzig Thomas Bernd, Rosano Giuseppe M C, Anker Stefan D
机构信息
Relaxera GmbH & Co. KG, Bensheim, Germany.
MHB Medizinische Hochschule Brandenburg, Neuruppin, Germany.
出版信息
ESC Heart Fail. 2020 Dec;7(6):3274-3277. doi: 10.1002/ehf2.13170. Epub 2020 Dec 15.
Abstract
摘要
相似文献
1
The (apparent) sacubitril/valsartan sex interaction in heart failure with preserved ejection fraction: not the result of relaxin effects but of BNP action?!
ESC Heart Fail. 2020 Dec;7(6):3274-3277. doi: 10.1002/ehf2.13170. Epub 2020 Dec 15.
2
Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
Eur Heart J. 2023 Aug 14;44(31):2982-2993. doi: 10.1093/eurheartj/ehad344.
3
Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
JACC Heart Fail. 2020 May;8(5):372-381. doi: 10.1016/j.jchf.2020.03.002. Epub 2020 Mar 30.
4
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
Circulation. 2020 Feb 4;141(5):338-351. doi: 10.1161/CIRCULATIONAHA.119.044491. Epub 2019 Nov 17.
5
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1.
6
The Effect of Sacubitril/Valsartan on Left Ventricular Myocardial Deformation in Heart Failure with Preserved Ejection Fraction (PARAMOUNT trial).
J Card Fail. 2023 Jun;29(6):968-973. doi: 10.1016/j.cardfail.2023.03.019. Epub 2023 Apr 7.
7
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF Trial.
Circ Heart Fail. 2023 Mar;16(3):e010111. doi: 10.1161/CIRCHEARTFAILURE.122.010111. Epub 2023 Jan 25.
8
The Efficacy and Safety of Sacubitril/Valsartan Compared to Valsartan in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fractions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
J Clin Med. 2024 Mar 9;13(6):1572. doi: 10.3390/jcm13061572.
9
Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial.
JAMA Cardiol. 2023 Apr 1;8(4):366-375. doi: 10.1001/jamacardio.2023.0065.
10
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
Eur Heart J. 2021 Sep 21;42(36):3741-3752. doi: 10.1093/eurheartj/ehab499.
本文引用的文献
1
The anti-fibrotic actions of relaxin are mediated through AT R-associated protein phosphatases via RXFP1-AT R functional crosstalk in human cardiac myofibroblasts.
FASEB J. 2020 Jun;34(6):8217-8233. doi: 10.1096/fj.201902506R. Epub 2020 Apr 16.
2
Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial.
ESC Heart Fail. 2020 Jun;7(3):856-864. doi: 10.1002/ehf2.12694. Epub 2020 Apr 15.
3
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
Circulation. 2020 Feb 4;141(5):338-351. doi: 10.1161/CIRCULATIONAHA.119.044491. Epub 2019 Nov 17.
4
AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis.
J Am Soc Nephrol. 2019 Nov;30(11):2191-2207. doi: 10.1681/ASN.2019060597. Epub 2019 Sep 11.
5
B-type natriuretic peptide enhances fibrotic effects via matrix metalloproteinase-2 expression in the mouse atrium in vivo and in human atrial myofibroblasts in vitro.
Transl Res. 2019 Jun;208:30-46. doi: 10.1016/j.trsl.2019.02.007. Epub 2019 Feb 19.
6
Relaxin-2 for heart failure with preserved ejection fraction (HFpEF): Rationale for future clinical trials.
Mol Cell Endocrinol. 2019 May 1;487:54-58. doi: 10.1016/j.mce.2019.01.013. Epub 2019 Jan 16.
7
Testosterone plays a permissive role in angiotensin II-induced hypertension and cardiac hypertrophy in male rats.
Biol Reprod. 2019 Jan 1;100(1):139-148. doi: 10.1093/biolre/ioy179.
8
Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction.
Circ Heart Fail. 2016 Apr;9(4):e002763. doi: 10.1161/CIRCHEARTFAILURE.115.002763.
9
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.
10
Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease.
Hypertension. 2014 Aug;64(2):315-22. doi: 10.1161/HYPERTENSIONAHA.114.03594.
Zotero 插件